950192-23-1Relevant academic research and scientific papers
Modular synthesis of new bicyclic carbene precursors
Li, Jie,Yao, Jiaqi,He, Weiping,Yang, Fan,Liu, Xiaoming
, p. 951 - 954 (2019/11/22)
A series of new N-heterocyclic carbene (NHC) precursors, containing bicyclic pyrrolo[1,2-c]imidazole framework, were prepared from N-(tert-butoxycarbonyl)-L-proline (1-Boc-L-proline). The sequential attachment of nitrogen nucleophiles and subsequent ring
Chiral azo-heterocyclic carbene precursor compound with bicyclic framework and preparation method thereof
-
Paragraph 0042; 0043; 0044; 0045; 0058; 0060; 0061, (2019/01/22)
The invention discloses a chiral azo-heterocyclic carbene precursor compound with a bicyclic framework and a preparation method thereof. A series of the chiral azo-heterocyclic carbene precursor compound with the bicyclic framework is obtained by taking c
Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres
Cohen, Frederick,Koehler, Michael F.T.,Bergeron, Philippe,Elliott, Linda O.,Flygare, John A.,Franklin, Matthew C.,Gazzard, Lewis,Keteltas, Stephen F.,Lau, Kevin,Ly, Cuong Q.,Tsui, Vickie,Fairbrother, Wayne J.
scheme or table, p. 2229 - 2233 (2010/06/15)
A series of IAP antagonists based on thiazole or benzothiazole amide isosteres was designed and synthesized. These compounds were tested for binding to the XIAP-BIR3 and ML-IAP BIR using a fluorescence polarization assay. The most potent of these compound
INHIBITORS OF IAP
-
Page/Page column 77, (2008/12/08)
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1 - M - U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3', R4, R4' and R5, are as described herein.
INHIBITORS OF IAP
-
Page/Page column 54, (2008/06/13)
The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula (I): wherein Q, X1, X2, Y, Z1, Z2, Z3, Z4, R1, R2, R3, R3', R4, R4', R5, R6, R6' and n are as described herein.
